Avidity Biosciences Dirección
Dirección controles de criterios 2/4
El CEO de Avidity Biosciences es Sarah Boyce , nombrado en Oct 2019, tiene una permanencia de 5.08 años. compensación anual total es $11.14M, compuesta por 5.7% salario y 94.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.06% de las acciones de la empresa, por valor de $3.04M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 5.2 años, respectivamente.
Información clave
Sarah Boyce
Chief Executive Officer (CEO)
US$11.1m
Compensación total
| Porcentaje del salario del CEO | 5.7% |
| Permanencia del CEO | 5.1yrs |
| Participación del CEO | 0.06% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Avidity Biosciences: Risks And Potential
Dec 09We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Nov 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$280m |
| Jun 30 2024 | n/a | n/a | -US$252m |
| Mar 31 2024 | n/a | n/a | -US$229m |
| Dec 31 2023 | US$11m | US$635k | -US$212m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$193m |
| Mar 31 2023 | n/a | n/a | -US$192m |
| Dec 31 2022 | US$5m | US$601k | -US$174m |
| Sep 30 2022 | n/a | n/a | -US$162m |
| Jun 30 2022 | n/a | n/a | -US$148m |
| Mar 31 2022 | n/a | n/a | -US$128m |
| Dec 31 2021 | US$6m | US$570k | -US$118m |
| Sep 30 2021 | n/a | n/a | -US$96m |
| Jun 30 2021 | n/a | n/a | -US$78m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$823k | US$484k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$34m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$4m | US$104k | -US$25m |
Compensación vs. Mercado: La compensación total de Sarah($USD11.14M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD7.91M).
Compensación vs. Ingresos: La compensación de Sarah ha aumentado mientras la empresa no es rentable.
CEO
Sarah Boyce (52 yo)
5.1yrs
Permanencia
US$11,139,719
Compensación
Ms. Sarah Boyce is Director of Abcuro, Inc. from July 2024. She serves as Independent Director of Contineum Therapeutics, Inc Since June 2024. She has been President, Chief Executive Officer and Director a...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 12yrs | US$260.31k | 0.064% $ 3.2m | |
| President | 5.1yrs | US$11.14m | 0.060% $ 3.0m | |
| Chief Financial & Chief Business Officer | 4.5yrs | US$4.48m | 0.0065% $ 325.6k | |
| Chief Scientific & Technical Officer | 3.8yrs | US$4.89m | 0.072% $ 3.6m | |
| Chief Human Resources Officer | 4.3yrs | US$3.73m | 0.079% $ 4.0m | |
| Distinguished Scientist | 1.8yrs | US$3.03m | 0.13% $ 6.5m | |
| Chief Strategy Officer | less than a year | US$235.31k | 0% $ 0 | |
| Scientific Founder | 12.8yrs | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | 12.8yrs | sin datos | sin datos | |
| Chief Legal Officer & Corporate Secretary | less than a year | sin datos | sin datos | |
| Consultant | less than a year | sin datos | sin datos | |
| Chief Program Officer | 1.8yrs | sin datos | sin datos |
3.8yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RNA se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 12yrs | US$260.31k | 0.064% $ 3.2m | |
| President | 5.1yrs | US$11.14m | 0.060% $ 3.0m | |
| Distinguished Scientist | 1.8yrs | US$3.03m | 0.13% $ 6.5m | |
| Scientific Founder | no data | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.6yrs | US$245.31k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.3yrs | US$244.31k | 0% $ 0 | |
| Observer | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.3yrs | US$245.81k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
5.2yrs
Permanencia media
58.5yo
Promedio de edad
Junta con experiencia: La junta directiva de RNA se considera experimentada (5.2 años de antigüedad promedio).